Barinthus Biotherapeutics Statistics
Total Valuation
BRNS has a market cap or net worth of $26.64 million. The enterprise value is -$28.21 million.
| Market Cap | 26.64M |
| Enterprise Value | -28.21M |
Important Dates
The last earnings date was Thursday, April 30, 2026, before market open.
| Earnings Date | Apr 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BRNS has 40.85 million shares outstanding. The number of shares has increased by 2.40% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 40.85M |
| Shares Change (YoY) | +2.40% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 11.74% |
| Owned by Institutions (%) | 31.12% |
| Float | 27.26M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.40 |
| P/TBV Ratio | 0.51 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.05, with a Debt / Equity ratio of 0.17.
| Current Ratio | 6.05 |
| Quick Ratio | 5.60 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -852.27 |
Financial Efficiency
Return on equity (ROE) is -57.49% and return on invested capital (ROIC) is -26.50%.
| Return on Equity (ROE) | -57.49% |
| Return on Assets (ROA) | -23.21% |
| Return on Invested Capital (ROIC) | -26.50% |
| Return on Capital Employed (ROCE) | -54.24% |
| Weighted Average Cost of Capital (WACC) | 1.54% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.74M |
| Employee Count | 14 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -169,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -35.44% in the last 52 weeks. The beta is -0.40, so BRNS's price volatility has been lower than the market average.
| Beta (5Y) | -0.40 |
| 52-Week Price Change | -35.44% |
| 50-Day Moving Average | 0.63 |
| 200-Day Moving Average | 0.84 |
| Relative Strength Index (RSI) | 47.37 |
| Average Volume (20 Days) | 17,855 |
Short Selling Information
The latest short interest is 14,337, so 0.06% of the outstanding shares have been sold short.
| Short Interest | 14,337 |
| Short Previous Month | 7,742 |
| Short % of Shares Out | 0.06% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.73 |
Income Statement
| Revenue | n/a |
| Gross Profit | -336,000 |
| Operating Income | -43.47M |
| Pretax Income | -52.50M |
| Net Income | -52.31M |
| EBITDA | -41.60M |
| EBIT | -43.47M |
| Earnings Per Share (EPS) | -$1.29 |
Balance Sheet
The company has $65.86 million in cash and $11.01 million in debt, with a net cash position of $54.85 million or $1.34 per share.
| Cash & Cash Equivalents | 65.86M |
| Total Debt | 11.01M |
| Net Cash | 54.85M |
| Net Cash Per Share | $1.34 |
| Equity (Book Value) | 66.48M |
| Book Value Per Share | 1.63 |
| Working Capital | 60.66M |
Cash Flow
In the last 12 months, operating cash flow was -$36.44 million and capital expenditures -$32,000, giving a free cash flow of -$36.48 million.
| Operating Cash Flow | -36.44M |
| Capital Expenditures | -32,000 |
| Depreciation & Amortization | 1.87M |
| Net Borrowing | n/a |
| Free Cash Flow | -36.48M |
| FCF Per Share | -$0.89 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BRNS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.40% |
| Shareholder Yield | -2.40% |
| Earnings Yield | -196.38% |
| FCF Yield | -136.93% |
Analyst Forecast
The average price target for BRNS is $5.50, which is 743.43% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $5.50 |
| Price Target Difference | 743.43% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |